EA200702595A1 - Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов - Google Patents
Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитовInfo
- Publication number
- EA200702595A1 EA200702595A1 EA200702595A EA200702595A EA200702595A1 EA 200702595 A1 EA200702595 A1 EA 200702595A1 EA 200702595 A EA200702595 A EA 200702595A EA 200702595 A EA200702595 A EA 200702595A EA 200702595 A1 EA200702595 A1 EA 200702595A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- platelet aggregation
- inhibitor
- nanoparticles containing
- composition
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000002105 nanoparticle Substances 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 abstract 3
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 abstract 3
- 229940127218 antiplatelet drug Drugs 0.000 abstract 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 abstract 3
- 229960004588 cilostazol Drugs 0.000 abstract 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68362005P | 2005-05-23 | 2005-05-23 | |
| PCT/US2006/019905 WO2008030209A2 (en) | 2005-05-23 | 2006-05-23 | Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200702595A1 true EA200702595A1 (ru) | 2008-12-30 |
Family
ID=39153748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200702595A EA200702595A1 (ru) | 2005-05-23 | 2006-05-23 | Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090297596A1 (https=) |
| EP (1) | EP1937218A2 (https=) |
| JP (1) | JP2008545808A (https=) |
| KR (1) | KR20080047509A (https=) |
| CN (1) | CN101287451A (https=) |
| BR (1) | BRPI0609982A2 (https=) |
| CA (1) | CA2611506A1 (https=) |
| EA (1) | EA200702595A1 (https=) |
| IL (1) | IL187567A0 (https=) |
| NO (1) | NO20076588L (https=) |
| WO (1) | WO2008030209A2 (https=) |
| ZA (1) | ZA200710000B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9775819B2 (en) | 2009-09-16 | 2017-10-03 | R.P. Scherer Technologies, Llc | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
| US8779146B2 (en) | 2010-04-28 | 2014-07-15 | Nuformix Limited | Cilostazol cocrystals and compositions |
| US9012511B2 (en) | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
| KR101282847B1 (ko) * | 2011-07-27 | 2013-07-05 | 조선대학교산학협력단 | 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물 |
| KR20150027800A (ko) | 2012-06-15 | 2015-03-12 | 고에키 자이단 호징 센탄 이료 신코 자이단 | 경도 인지 장해의 예방 및/또는 치료제 |
| TWI697337B (zh) * | 2013-08-07 | 2020-07-01 | 學校法人近畿大學 | 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法 |
| CN103980326A (zh) * | 2014-05-05 | 2014-08-13 | 珀莱雅化妆品股份有限公司 | 一种超临界co2反胶束萃取红景天苷的制备方法 |
| KR101869406B1 (ko) * | 2015-11-25 | 2018-07-24 | 한국유나이티드제약 주식회사 | 방출제어형 경질캡슐 제제 |
| CN112592379B (zh) * | 2020-12-18 | 2021-11-16 | 广东药科大学 | 一种β-D-葡萄糖短链脂肪酸酯化合物及其制备方法和应用 |
| CN114796217B (zh) * | 2021-01-29 | 2025-01-24 | 南京宁丹新药技术有限公司 | 一种含有西洛他唑的组合物在制备治疗脑血管病药物中的应用 |
| CN117982677B (zh) * | 2024-02-05 | 2025-09-09 | 沈阳药科大学 | 背载血小板激活抑制剂纳米粒的工程化血小板及其制备方法及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| WO1993025190A1 (en) * | 1992-06-10 | 1993-12-23 | Eastman Kodak Company | Surface modified nsaid nanoparticles |
| US6117455A (en) * | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
| US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| EP1126826B3 (en) * | 1998-11-02 | 2019-05-15 | Alkermes Pharma Ireland Limited | Multiparticulate modified release composition of methylphenidate |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| EG23951A (en) * | 1999-03-25 | 2008-01-29 | Otsuka Pharma Co Ltd | Cilostazol preparation |
| WO2001023000A1 (fr) * | 1999-09-30 | 2001-04-05 | Otsuka Pharmaceutical Company, Limited | Preparations d'enrobage solubles dans le tube digestif inferieur |
| JP4751556B2 (ja) * | 2000-02-28 | 2011-08-17 | ジーンシーグス， インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| ATE419834T1 (de) * | 2000-11-20 | 2009-01-15 | Elan Pharma Int Ltd | Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren |
| US6573382B2 (en) * | 2001-06-29 | 2003-06-03 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| EP1423175B1 (en) * | 2001-08-08 | 2013-10-02 | Brown University Research Foundation | Methods for micronization of hydrophobic drugs |
| TW200301135A (en) * | 2001-12-27 | 2003-07-01 | Otsuka Maryland Res Inst Inc | Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
| JP2007501839A (ja) * | 2003-08-08 | 2007-02-01 | エラン ファーマ インターナショナル リミテッド | 新規メタキサロン組成物 |
| US20050255155A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Modified release cilostazol compositions |
| KR20080008403A (ko) * | 2005-05-10 | 2008-01-23 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 클로피도그렐 제제 |
| CA2611741A1 (en) * | 2005-06-13 | 2006-12-28 | Elan Pharma International, Limited | Nanoparticulate clopidogrel and aspirin combination formulations |
-
2006
- 2006-05-23 EA EA200702595A patent/EA200702595A1/ru unknown
- 2006-05-23 BR BRPI0609982-3A patent/BRPI0609982A2/pt not_active Application Discontinuation
- 2006-05-23 CA CA002611506A patent/CA2611506A1/en not_active Abandoned
- 2006-05-23 US US11/568,835 patent/US20090297596A1/en not_active Abandoned
- 2006-05-23 JP JP2008533328A patent/JP2008545808A/ja active Pending
- 2006-05-23 KR KR1020077030037A patent/KR20080047509A/ko not_active Withdrawn
- 2006-05-23 WO PCT/US2006/019905 patent/WO2008030209A2/en not_active Ceased
- 2006-05-23 CN CNA2006800269859A patent/CN101287451A/zh active Pending
- 2006-05-23 EP EP06851355A patent/EP1937218A2/en not_active Withdrawn
-
2007
- 2007-11-20 ZA ZA200710000A patent/ZA200710000B/xx unknown
- 2007-11-22 IL IL187567A patent/IL187567A0/en unknown
- 2007-12-20 NO NO20076588A patent/NO20076588L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200710000B (en) | 2009-12-30 |
| WO2008030209A2 (en) | 2008-03-13 |
| NO20076588L (no) | 2008-02-20 |
| KR20080047509A (ko) | 2008-05-29 |
| EP1937218A2 (en) | 2008-07-02 |
| WO2008030209A3 (en) | 2008-07-03 |
| US20090297596A1 (en) | 2009-12-03 |
| BRPI0609982A2 (pt) | 2010-05-18 |
| JP2008545808A (ja) | 2008-12-18 |
| CN101287451A (zh) | 2008-10-15 |
| CA2611506A1 (en) | 2006-11-23 |
| IL187567A0 (en) | 2011-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073559L (no) | Nanopartiklulaere tacrolimus-formuleringer | |
| NO20076588L (no) | Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring | |
| NO20073334L (no) | Nanopartikulaert benzotiofenformuleringer | |
| EA200702638A1 (ru) | Стабильная композиция (рецептура) с наночастицами ацетаминофена | |
| AR063940A1 (es) | Formulaciones de posaconazol nanoparticulado | |
| JP2009531457A5 (https=) | ||
| BR0313629B1 (pt) | composiÇço detergente bifÁsica lÍquida aquosa de limpeza pessoal. | |
| ATE520757T1 (de) | Polykationische viskoelastische zusammensetzungen | |
| DE602004021107D1 (de) | Meloxican-formulierungen in nanoteilchenform | |
| DE602005019336D1 (de) | Zusammensetzung mit oberflächenmodifizierenden eigenschaften | |
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| DK1471887T3 (da) | Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel | |
| IL196543A (en) | Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders | |
| EA200970981A1 (ru) | Пептидная смесь в качестве стабилизатора вина | |
| BR0313628A (pt) | Composições lìquidas de limpeza | |
| HN2008000582A (es) | Composiciones de suplementos de hierro de tolerancia mejorada | |
| BR112017023720A2 (pt) | formulações de inibidor de corrosão | |
| EA201400666A1 (ru) | Противомикробная композиция | |
| NO20076628L (no) | Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser | |
| EA201400664A1 (ru) | Противомикробная композиция | |
| EA200501513A1 (ru) | Замещённые 1, 4 - диазепины и их применения | |
| WO2007067519A3 (en) | The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions | |
| EA200900862A1 (ru) | Производные простациклина | |
| ZA202206588B (en) | Metal salts and uses thereof | |
| GB2442366A (en) | Nanoparticulate and controlled release compositions comprising prostaglandin derivatives |